hematopoietic specific Cre mouse lines for conditional alleles
Conditional deletion of Target limits genetic change to the lineage you choose. That precision matters for oncology, immunology, and metabolic work where systemic loss would confound interpretation. After you confirm your Cre specificity, crossing to Target floxed stock yields interpretable cohorts. For hematopoietic work, plan Cre specificity, reporter crosses, and baseline phenotyping before you scale.
Drivers used in hematopoietic programs
Conditional knockout keeps hematopoietic as the experimental theater while the rest of the animal retains a wild type allele. That pattern mirrors somatic mutation in patients and avoids systemic compensation that can erase subtle phenotypes. It is often preferred when a germline null is lethal, weak, or confounded by developmental rescue. Knockin and humanized formats preserve regulatory context at the endogenous locus. For hematopoietic focused programs, that matters when expression timing, splice isoforms, or allele dosage drive biology. Random integration transgenics can still help, but targeted alleles usually give cleaner pharmacology readouts.
Popular floxed genes crossed to hematopoietic drivers
Frequently asked questions
What does hematopoietic specific Cre mean?
hematopoietic specific Cre drivers recombine floxed alleles primarily in that lineage. Practical work still demands reporter crosses to verify efficiency in your facility because genetic background and copy number nudge leak profiles.
Should I use inducible CreERT2 for hematopoietic studies?
Inducible systems help when developmental deletion confounds adult phenotypes or when you need tight timing around injury or tumor onset. Tamoxifen protocols carry their own controls, which we document in project planning.
Where do I find floxed models to pair with these drivers?
Our catalog lists floxed conditional lines by gene. If your favorite target is not listed, we quote custom flox builds and crossing plans so you reach cohort size on a clear schedule.